Drug Profile
Olokizumab - R-Pharm
Alternative Names: Anti-IL6 - R-Pharm; Artlegia; CDP-6038Latest Information Update: 01 Jan 2024
Price :
$50
*
At a glance
- Originator UCB
- Developer R-Pharm; UCB
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease
- Phase III Inflammation
Most Recent Events
- 10 Nov 2023 Pooled efficacy data from the phase III CREDO 1, CREDO 2 and CREDO 3 trial in Rheumatoid arthritis presented at the ACR Convergence 2023 (ACR-2023)
- 31 May 2023 Updated efficacy data from the phase III CREDO 4 trial in Rheumatoid arthritis presented at the at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)
- 04 Nov 2022 Efficacy and safety data from a phase III CREDO 2 trial in Rheumatoid arthritis presented at ACR Convergence 2022 (ACR-2022)